• M Harrison Snyder, Andy Yu-Der Wang, Leonel Ampie, Danyas Sarathy, Ajay Chatrath, Ashok R Asthagiri, Christopher I Shaffrey, Justin S Smith, Mark E Shaffrey, Chun-Po Yen, Avery L Buchholz, Hasan R Syed, James Kryzanski, Julian K Wu, and Carl B Heilman.
• Department of Neurosurgery, University of Virginia Hospital, Charlottesville, VA, USA; Department of Neurosurgery, Tufts Medical Center, Boston, MA, USA. Electronic address: harrisonsnydermd@gmail.com.
• World Neurosurg. 2022 Nov 1; 167: e1006e1016e1006-e1016.

ObjectivePrimary spinal cord astrocytomas are rare, fatal, and poorly studied.MethodsThis study included a 2-center, retrospective analysis of primary spinal cord astrocytoma patients from 1997 to 2020. Patients with drop metastases or without at least one follow-up were excluded.ResultsSeven World Health Organization grade I, 6 grade II, 7 grade III, and 4 grade IV astrocytoma patients were included. Older patients had higher grades (median 20 years in grade I vs. 36.5 in grade IV). The median follow-up was 15 months. Thirteen patients were discharged to rehabilitation. Eight patients demonstrated radiographic progression. Adjuvant therapy was utilized more in higher grades (5 of 13 grades III vs. all 11 grades IIIIV). Six patients died (1 death in grades III vs. 5 in grades IIIIV). Ten patients had worsened symptoms at the last follow-up. The median progression-free survival in grade I, II, III, and IV tumors was 116, 36, 8, and 8.5 months, respectively. The median overall survival in grade I, II, III, and IV tumors was 142, 69, 19, and 12 months, respectively. Thrombotic complications occurred in 2 patients, one with isocitrate dehydrogenasewild type glioblastoma.ConclusionsOutcomes worsen with higher grades and lead to difficult postoperative periods. Clinicians should be vigilant for thromboembolic complications. Further research is needed to understand these rare tumors.Copyright © 2022 Elsevier Inc. All rights reserved.

14 keywords...

hide…